Inclusion Criteria

DISEASE CHARACTERISTICS:

- Patients must have metastatic colorectal cancer that has been histologically or
cytologically confirmed

- Histologic confirmation can be obtained from the primary tumor with appropriate
imaging studies confirming metastatic spread

- No known central nervous system or brain metastasis that are either symptomatic or
untreated

- If a patient has a resection of the metastasis and is no longer symptomatic, the
patient is eligible for the study

- Patients with neurological symptoms must undergo a CT scan/MRI of the brain to
exclude brain metastasis

PATIENT CHARACTERISTICS:

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2

- Life expectancy ≥ 3 months

- Absolute neutrophil count (ANC) ≥ 1,500/mm^3

- Peripheral platelet count (PLT) ≥ 100,000/mm^3

- Hemoglobin (HgB) > 9.0 g/dL

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

- Aspartate transaminase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver
involvement)

- Alkaline phosphatase ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement)

- Creatinine ≤ 1.5 x ULN

- No calculated creatinine clearance < 60 mL/minute

- NOTE: If calculated creatinine clearance does not meet eligibility requirement,
a 24-hour urine can be collected for a creatinine clearance, and the patient can
be enrolled if measured creatinine clearance ≥ 60 mL/minute.

- INR < 1.5 x ULN unless patients are receiving anti-coagulation therapy

- Patients receiving prophylactic anti-coagulation therapy with an agent such as
warfarin or heparin are allowed to participate if INR ≤ 3.0

- UPC ratio < 1 or urine dipstick < 2+

- NOTE: Urine protein must be screened by urine analysis for urine protein
creatinine (UPC) ratio or by dipstick. For UPC ratio ≥ 1.0 or urine dipstick ≥
2+, 24-hour urine protein must be obtained and the level should be < 1,000 mg.

- No men of childbearing potential who are unwilling to employ adequate contraception
during and for 6 months after the last dose of bevacizumab

- Ability to complete questionnaire(s) by themselves or with assistance

- Willing to provide mandatory blood samples for correlative research purposes

- No co-morbid systemic illnesses or other severe concurrent disease that, in the
judgment of the investigator, would make the patient inappropriate for entry into
this study or interfere significantly with the proper assessment of the safety and
adverse events of the prescribed regimens

- No immunocompromised patients (other than that related to the use of corticosteroids)
including patients known to be HIV positive with CD4 < 100 cells/uL

- No uncontrolled intercurrent illness including, but not limited to:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness/social situations that would limit compliance with study
requirements

- No other active malignancy ≤ 3 years prior to randomization EXCEPT for nonmelanotic
skin cancer or carcinoma-in-situ of the cervix

- No New York Heart Association (NYHA) classification III or IV congestive heart
failure

- No inadequately controlled hypertension (systolic blood pressure of > 150 mm Hg or
diastolic blood pressure > 100 mm Hg on anti-hypertensive medications)

- No significant traumatic injury ≤ 28 days prior to randomization

- No active or recent hemoptysis (≥ ½ teaspoon of bright red blood per episode) ≤ 30
days prior to randomization

- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess ≤ 6 months prior to randomization

- No serious non-healing wound, active ulcer, or untreated bone fracture

- NOTE: Patients with fractures secondary to metastatic disease are eligible after
appropriate radiotherapy.

- No history of hypertensive crisis or hypertensive encephalopathy

- No patient that has experienced any arterial thromboembolic events including, but not
limited to:

- Myocardial infarction

- Stroke

- Transient ischemic attack (TIA)

- Cerebrovascular accident

- Unstable angina ≤ 6 months prior to randomization

- Congestive heart failure requiring use of ongoing maintenance therapy for
life-threatening ventricular arrhythmias

- No significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent
peripheral arterial thrombosis ≤ 6 months prior to randomization

- No evidence or history of bleeding diathesis (greater than normal risk of bleeding),
coagulopathy (in the absence of therapeutic anticoagulation), or hemorrhage/bleeding
event > grade 3 ≤ 4 weeks prior to randomization

- No known hypersensitivity to any of the components of 5-fluorouracil/leucovorin,
capecitabine, oxaliplatin, or bevacizumab

- No clinically significant peripheral neuropathy at the time of randomization (defined
in the NCI Common Terminology Criteria for Adverse Events [CTCAE] v4.0 as ≥ grade 2
neurosensory or neuromotor toxicity)

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy, radiation therapy, immunotherapy, or biological therapy for
recurrent or metastatic colorectal cancer

- NOTE: Prior chemotherapy or radiotherapy is permitted if they had been
administered as adjuvant or neoadjuvant therapy and a complete surgical
resection of the original colorectal cancer had been achieved.

- No progressive disease ≤ 12 months of completing oxaliplatin-containing adjuvant
therapy

- No prior radiation to > 30% of the bone marrow at any time

- No major surgical procedures or open biopsy ≤ 28 days prior to randomization or
anticipation of need for elective or planned major surgical procedure during the
course of the study

- No core biopsy or other minor surgical procedures ≤ 7 days prior to randomization

- NOTE: Placement of a vascular access device is allowed.

- If there is a history of prior malignancy, patients must not be receiving other
specific treatment (other than hormonal therapy) for this prior cancer

- Not receiving any other investigational agent which would be considered as a
treatment for the primary neoplasm

- Patients receiving full-dose anticoagulants are eligible provided the patient has
been on a stable dose, for at least 2 weeks, of low molecular weight heparin or
warfarin and has an INR range 2-3

- No aspirin doses > 325 mg daily